| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H14N2O2S |
| Molecular Weight | 334.392 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1SN(C(=O)N1CC2=CC=CC=C2)C3=CC=CC4=C3C=CC=C4
InChI
InChIKey=PMJIHLSCWIDGMD-UHFFFAOYSA-N
InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
| Molecular Formula | C19H14N2O2S |
| Molecular Weight | 334.392 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tideglusib (NP031112, NP-12, Nypta, Noscira SA, Madrid, Spain), a drug, which belongs to the thiadiazolidinone family, is a GSK-3β inhibitor. Tideglusib was in phase II clinical trials for the treatment of Alzheimer disease (AD) and progressive supranuclear palsy. Participants showed no benefit on either of the primary outcome measures or exploratory endpoints and further development in the drug was halted for these two disease. However, Tideglusib is on phase II clinical trial to determine whether drug is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
Route of Administration:
Oral
Tideglusib is an irreversible inhibitor of GSK-3β. The interaction of tideglusib with GSK-3β, binding studies with radioactive compound were performed. [35S]tideglusib (207 Bq/nmol) at 55 μM was incubated with 5 μM GSK-3β for 1 h at 25 °C in 315 μl of 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.1 mM EGTA.
